Thymosin β4: a natural therapeutic molecule with growing medical potential

Article about TB-500 (43aa) – heart and anti-aging


Article about TB-500 (43aa) – eyes, skin, hair


Article on TB-500 (43aa) – brain


Article about TB-500 (43aa) – liver and kidneys

Explanation of names

Thymosin β4 is a peptide composed of 43 amino acids. It is also commonly called TB-500. This is somewhat misleading, because officially the TB-500 peptide is a fragment of Thymosin β4 made up of 4 or 7 of its amino acids. In practice, when people say TB-500, most mean Thymosin β4 (43aa) – a very well-researched peptide for regeneration.

Our recommendation is that in order not to confuse these substances you should always say the amount of amino acids in the peptide:

• Thymosin β4 always has 43 amino acids in official and colloquial language.
• TB-500 (43aa) – it refers to Thymosin β4 with 43 amino acids
• TB-500 (4aa) – refers to a Thymosin β4 fragment containing only 4 amino acids. It is less researched.
• Tb-500 (7aa) – may also occur in a 7-amino acid version.

Description of the potential effects of Thymosin β4 based on the literature. (This is not a product description, disclaimer at the bottom of the page)

Thymosin β4 (Tβ4), also known as timbetazin, is a small protein composed of 43 amino acids. It occurs naturally in the human and mouse body. Scientists have also created laboratory (recombinant) versions of it for use in research and early medical testing. Its chemical formula is C₂₁₂H₃₅₀N₅₆O₇₈S, and its mass is about 4963 units (daltons) [1].

It is best known for its healing and protective properties in the body. Studies show that it helps wounds heal faster, promotes the growth of new blood vessels and reduces swelling, scarring and organ damage. It works by helping cells move to the site of injury, increasing the body's natural healing signals (such as VEGF through HIF-1α) and protecting tissues such as the heart, lungs, liver and bones. It also appears to activate processes such as autophagy, which helps remove damaged cells.

It is possible to purchase a chemical reagent containing TB-500 43 aa For Invitro studies.

Amino acids in thymosin beta 4 protein [1].

Because of these benefits, it is being tested for a range of medical applications - from treating heart damage and poor circulation to improving skin healing. One version, called RGN-259, is being tested as an eye drop to treat a rare corneal disease. A safety study in healthy volunteers has already been completed, showing growing interest in this multifunctional therapeutic peptide in medical research.

Thymosin β4 shows safety and predictable pharmacokinetics

In the first human clinical trial, Wang et al (2021) tested a laboratory version of thymosin β4 (called NL005) on healthy adult volunteers in China [2]. The study consisted of two parts: one group received a single intravenous dose ranging from 0.05 to 25.0 micrograms per kilogram, while the other group received daily intravenous doses of 0.5, 2.0 or 5.0 micrograms per kilogram for 10 days. The treatment was well tolerated in both groups - there were no serious side effects or dose-limiting problems. In the single-dose group, about 57% participants reported mild or moderate side effects, which was lower than the 70% reported in the placebo group. In the repeated-dose group, 67% treated participants had mild problems, compared to 83% in the placebo group. Most of the side effects were harmless and temporary, such as minor changes in lab results, ECG readings or tumor markers.

The way the drug was processed by the body was also predictable. In the single-dose group, maximum blood concentrations increased with increasing dose, from 1.99 ng/ml at the lowest dose to 230.07 ng/ml at the highest dose. Overall exposure to the drug also increased proportionally. The half-life (the time the drug remains in the body) increased slightly with higher doses, from about 0.5 to 2.1 hours. In the group receiving multiple doses, the drug did not accumulate in the body for 10 days. The rate at which the drug was removed from the body and the volume at which it diffused were stable. Importantly, very few participants showed any immune response to the drug - only one in the single-dose group and two in the multiple-dose group, and these reactions were temporary. These results show that the drug is safe, does not induce a significant immune system response, and behaves consistently in the body, making it a good candidate for future studies, including for the treatment of myocardial infarction.

Thymosin β4 safely relieves symptoms of severe dry eye syndrome

Thymosin β4-containing eye drops provide significant relief from severe dry eye syndrome symptoms. Sosne et al (2015) conducted a phase 2 clinical trial to test 0.1% thymosin β4-containing eye drops (named RGN-259) in patients with severe dry eye syndrome, including those with dry eye due to graft-versus-host disease (GVHD) [3]. Patients used drops six times a day for 28 days, followed by no treatment for 28 days. On day 56, patients using RGN-259 reported a 35.1% decrease in eye discomfort and a 59.1% decrease in ocular surface damage symptoms compared to the placebo group. Other symptoms such as tear stability and tear volume also improved. There were no safety issues, and the treatment was well tolerated. These results support the suitability of RGN-259 as a potential treatment for people with severe dry eye syndrome.

Thymosin β4 shows a wide safety margin

Intravenous use of thymosin β4 shows a wide safety margin in healthy individuals. In another study, Ruff et al (2010) tested synthetic thymosin β4 in healthy volunteers using four different intravenous doses - 42, 140, 420 and 1260 mg [4]. After checking safety, they administered the same doses once a day for 14 days. The treatment was well tolerated in both phases. Any side effects were mild to moderate and there were no serious reactions. The mode of action of the drug in the body (pharmacokinetics) increased in proportion to the dose, and the time it remained in the body was longer at higher doses. These results support further studies of thymosin β4 in conditions associated with poor blood flow, such as stroke or myocardial infarction.

Thymosin β4 accelerates healing of chronic leg ulcers

Topically applied thymosin β4 gel accelerates the healing of leg ulcers. In a phase 2 clinical trial conducted at eight centers in Europe, Guarnera et al (2010) tested topically applied thymosin β4 gel (including the 0.03% version) in 73 patients with chronic leg ulcers caused by poor blood flow (venous ulcers) [5]. The treatment was used along with standard care, such as compression bandages and wound debridement. The 0.03% gel proved most effective: approximately 25% patients experienced complete wound healing within three months, especially in those with mild-to-moderate ulcers. The treatment was safe and no serious side effects were observed. These healing effects confirm previous laboratory findings that thymosin β4 promotes skin regeneration by stimulating skin cell movement, collagen production and the growth of new blood vessels.

Study on moderate dry eye syndrome shows partial benefit

In a Phase II clinical trial using a specialized Controlled Adverse Environment (CAE™) stress model, Sosne and Ousler (2015) studied the effect of eye drops containing 0.1% thymosin β4 (RGN-259) in 72 adults with moderate to severe dry eye syndrome [6]. This single-center, randomized, double-blind, placebo-controlled study lasted 28 days and included six scheduled visits over 32 days. Participants were randomly assigned to a group receiving RGN-259 or placebo. The study's main objectives - reducing eye discomfort and lower corneal discoloration - showed no statistically significant improvement at the scheduled measurement point on day 29. However, several other results were positive for the treatment group. On Day 28, discomfort caused by CAE™ exposure decreased by 27% compared to placebo, and central and upper corneal health improved significantly. Other symptoms such as eye redness, tear stability and daily symptom tracking also improved. There were no drug-related side effects, and safety assessments showed no problems during various eye health tests. Although the primary endpoints were not reached in the allotted time, these results show that Thymosin β4 was safe and showed many signs of benefit, suggesting the need for larger studies and perhaps a rescheduling of outcome measures.

Thymosin β4 in the treatment of chronic corneal ulcers

In a separate compassionate use case series, Dunn et al. (2010) studied four patients aged 47 to 84 with long-standing neurotrophic corneal ulcers caused by conditions such as hemiplegia (herpes zoster ophthalmicus) and diabetes [7]. These patients showed no improvement after conventional treatments such as antibiotics, moisturizers, steroid drops or protective lenses. They were given thymosin β4-containing eye drops (supplied by RegeneRx Biopharmaceuticals) four times a day for four weeks. The results showed individual improvement: in one patient, the corneal lesion healed completely within 25 days and remained closed until day 56; in another patient, there was a significant reduction in the size of the lesion by day 28; in a third patient, there was delayed but progressive healing until day 70; and in a fourth patient, the lesion healed by day 42 and remained closed. None of the patients reported pain or side effects, and all experienced increased comfort and reduced redness. Thymosin β4 is known to help repair eye tissue, reduce inflammation and regulate enzymes involved in healing, and this small series of studies speaks to the need for further clinical trials on difficult-to-treat corneal injuries.

Thymosin β4 reduces healing time

Animal and human studies have shown that thymosin β4 can accelerate wound healing and reduce the time it takes for wounds to close completely. In animal models using full-thickness skin wounds - such as in normal rats, diabetic mice, steroid-treated rats and aged mice - it consistently helped wounds heal faster [9]. In clinical trials involving patients with venous ulcers and sores, those who received thymosin β4 and healed did so about a month faster than those given a placebo. While animal studies have looked at the speed of wound healing, human studies have focused on the time it takes for these wounds to heal completely. It appears to work through a number of mechanisms involved in healing, including promoting cell movement, helping stem cells repair tissue, reducing inflammation, protecting cells from damage and possibly reducing the risk of infection. These results suggest that it is a versatile treatment for both normal and difficult-to-heal wounds. However, more research is still needed to confirm its benefits, determine the best dose and form, and identify the patients most likely to benefit.

Thymosin β4 gel in the treatment of venous leg ulcers

To test the use of thymosin β4 in venous leg ulcers, Guarnera et al (2007) designed a carefully controlled European study conducted in 10 hospitals in Italy and Poland [10]. The study was a randomized, double-blind, placebo-controlled trial with three dosage groups, each with 24 participants, and three of the four received thymosin β4. All participants also received standard wound care, including compression stockings and wound debridement. Participants applied thymosin β4 gel or placebo n y gel to the sores for 84 days, and a follow-up was conducted after another 14 days. The researchers measured how many ulcers had completely healed by the 84th day and how long, on average, it took to heal. They also closely monitored safety by checking blood levels of thymosin β4 and conducting weekly laboratory tests. At the time of the report, the study was still underway, with 21 subjects enrolled in the first group (lowest dose). Strengths of the study included a strict blinded trial, careful monitoring and accurate measurement of wound size. However, limitations included a small total sample size of 72 subjects and a lack of outcome data at this time.

Broad benefits of thymosin β4 in skin healing

Thymosin β4 promotes skin wound healing and tissue regeneration. A broader review by Kleinman and Sosne (2016) summarized both laboratory and human studies on the effects of thymosin β4 on skin healing [8]. This peptide occurs naturally in human tissues and blood platelets and has been tested in various forms—such as topical gels, injections, and synthetic or dimeric versions—in both animals and humans. In animal models, thymosin β4 consistently helped wounds heal faster, even in difficult cases such as aging, diabetes, steroid use, or poor blood circulation. It promoted blood vessel growth, skin cell migration, and an orderly collagen structure while reducing scarring. In models with restricted blood flow, it also improved skin flap survival and recovery from limb ischemia, especially when combined with slow-release systems. Animal studies showed that slightly higher healing rates occurred with dimeric (double) forms of the peptide compared to the regular monomer.

Early human safety studies found no significant side effects or measurable levels of the drug in the blood after topical application. Three small Phase II studies conducted on people with chronic wounds such as bedsores, venous ulcers and pemphigus showed faster healing with gels containing 0.02-0.03% thymosin β4, especially between weeks 4 and 9 of treatment [8]. Higher or lower doses were not as effective, confirming the importance of optimal dosing. The peptide works in several ways: it protects cells by reducing inflammation, limiting cell damage and controlling harmful molecules; it promotes repair by helping skin and blood vessel cells to move and grow; and it may even promote regeneration by activating stem cells and hair follicles. These effects are linked to specific fragments of the peptide and various cell signaling pathways, including those involving ATP receptors, PI3K/AKT and heat shock proteins.

In practice, the use of 0.02-0.03% gel once daily for 8 to 12 weeks appears to be a promising approach for chronic wounds. Thymosin β4 has been shown to be safe in about 200 patients in Phase I and II studies, and even in studies with high intravenous doses, no serious side effects were reported [8]. Although thymosin β4 can promote cell migration and blood vessel growth, features that are sometimes associated with the development of cancer, no tumor-promoting effects have been observed in skin studies, and some evidence even suggests an anti-tumor effect for some cancers, such as multiple myeloma. The review concludes that future studies should aim to adjust dosage depending on the type of wound, better define the peptide's action at the molecular level, and test more advanced versions, such as dimeric forms or active fragments, in larger human studies [8].

Thymosin β4 in epidermolysis bullosa (EB)

Thymosin β4 has shown therapeutic potential in the treatment of pemphigus and other severe skin injuries. It has also shown potential in treating severe skin injuries such as pemphigus (EB), a rare genetic disease that causes fragile skin and frequent blistering. The condition is painful and increases the risk of infection, scarring, disability and even skin cancer. Currently, treatment is mainly supportive and provides limited relief [11]. It is a small peptide found naturally in most tissues and fluids, including wound fluids, that aids a wide range of healing processes. It helps reduce inflammation, prevents cell death, stimulates blood vessel formation, reduces scar formation and may protect against infection.

Different regions of the peptide have specific roles. For example, some sections help reduce inflammation and fibrosis, while others help cells survive, promote cell movement, stimulate the formation of new blood vessels, or promote the repair of heart tissue. In terms of mechanisms, it helps reduce inflammation by blocking certain cellular signals such as NF-κB, protects skin cells from damage, increases nutrient delivery by stimulating the formation of new blood vessels, improves skin cell migration and binding, and reduces scarring by improving the way collagen is deposited in the skin. It also has antimicrobial and antioxidant properties that can help prevent infection and oxidative stress damage [11].

Three topical doses were tested in patients with EB in a phase II study involving about 30 participants. Although the highest goal of complete healing by day 56 was not achieved, the group receiving thymosin β4 showed smaller wound areas at day 14 compared to the placebo group. The U.S. Food and Drug Administration (FDA) no longer requires complete wound closure as a primary outcome in EB studies, meaning that partial improvement still counts. Thymosin β4's ability to reduce pain, improve healing and facilitate care makes it a suitable candidate for the treatment of EB, especially given that newer gene therapies remain complex and expensive. In all skin studies to date, it has shown a favorable safety profile, even in elderly, diabetic and EB patients [11].

Other potential health benefits based on animal studies

Improves glycemic control and insulin sensitivity

In mice with diabetes, thymosin β4 improves blood glucose regulation and increases insulin sensitivity in muscle tissue. In a study by Zhu et al (2012), researchers administered daily doses of thymosin β4 to mice with diabetes for 12 weeks to see if it would help regulate blood sugar levels [12]. Mice with diabetes (a special strain called KK Cg-Ay/J) were treated with 100 ng of thymosin β4 per 10 g of body weight by injection. Compared to untreated diabetic mice, those given thymosin β4 performed better on glucose tolerance tests, had lower HbA1c levels (a long-term marker of blood sugar), reduced triglyceride levels and higher levels of adiponectin (a hormone that helps increase the body's sensitivity to insulin). Importantly, it also improved the response of muscle cells to insulin by enhancing a signal called phosphorylated AKT. These effects were not observed in healthy mice, suggesting that it works specifically in the context of diabetes.

Restores blood flow and nerve function in diabetic neuropathy

Thymosin β4 repairs damaged microvessels and improves nerve function in models of diabetic neuropathy. Wang et al (2012) tested thymosin β4 on mice with type 2 diabetes that developed diabetic neuropathy (nerve damage caused by high blood sugar levels) [13]. It helped restore blood flow and blood vessel density in the sciatic nerve, which is the main nerve in the leg. It also improved the function of these nerves. In the diabetic nerves, it increased the level of a healing protein called angiopoietin-1 (Ang1) and decreased the level of angiopoietin-2 (Ang2), which is associated with blood vessel damage. These changes were observed in cells lining blood vessels and in Schwann cells, which support nerve health. In laboratory tests using human cells, it also helped protect blood vessel growth under high sugar conditions. Overall, these benefits appear to work through the PI3K/AKT pathway, which helps maintain blood vessel stability and function, which is important for repairing nerve damage in diabetes.

Revitalizes blood vessel cells from diabetic patients

Thymosin β4 restores key cellular functions in damaged vascular endothelial cells of diabetic patients. Su et al. (2022) studied how thymosin β4 affects vascular cells generated from stem cells taken from diabetic patients [14]. These lab-grown cells (called dia-hiPSC-EC) normally do not function well. When given 600 ng/ml of thymosin β4, these cells showed better survival, faster growth and slower aging. They also produced fewer harmful proteins, such as endothelin-1 (ET-1), which can cause blood vessel constriction, and MMP-1, which breaks down tissue. This didn't fix everything - it didn't restore cellular energy levels or some other imbalances - but it still helped in several important ways. When these treated cells were transplanted into mice with type diabetes that had poor circulation in their legs, blood flow in the legs improved significantly. The researchers concluded that this enhanced the survival and healing abilities of these patient-derived cells by activating AKT signals and reducing harmful inflammatory factors.

Improves skin regeneration in diabetic and aged mice

Thymosin β4 accelerates skin healing in mice with diabetes and older mice, even when administered as a short peptide. In a study by Philp et al (2003), researchers tested thymosin β4 on mice with diabetes (db/db) and very old mice (aged 26 months) that had deep skin wounds [15]. The goal was to see if it could help these wounds heal faster. The treatment was applied topically, using a PBS solution or hydrogel. In mice with diabetes, it improved wound shrinkage (reduced wound size) and increased the production of collagen, which helps restore the skin. In all mice with diabetes, complete skin coverage was observed by day 8, so there was little difference in keratinocyte (skin cell) migration. In older mice, which naturally heal more slowly, thymosin β4 helped significantly - it accelerated wound closure, improved keratinocyte movement toward the wound, and increased both wound contraction and collagen levels. Importantly, the type of formulation (PBS or hydrogel) did not affect the results - both worked equally well. To test whether a smaller portion of the thymosin β4 molecule could act on its own, the researchers used a short fragment consisting of seven amino acids called LKKTETQ. In aged mice, this small peptide worked just as well as the full-length thymosin β4, showing that the key therapeutic action comes from this particular part, which helps with cell movement and collagen remodeling through the actin cytoskeleton.

Promotes healing of diabetic burns

Thymosin β4 promotes skin burn healing in diabetics by improving blood circulation and reducing inflammation. Kim and Kwon (2014) studied thymosin β4 in mice with diabetes and severe skin burns. The burns were induced by hot water and covered an area of 10 mm [16]. Thymosin was injected near the wound at a dose of 5 mg/kg twice a week for two weeks. Compared to untreated mice, mice receiving thymosin β4 healed faster, produced more new tissue (granulation tissue) and had better blood vessel growth in the wound area. In addition, it reduced levels of a protein called RAGE, which is often found in high levels in people with diabetes and contributes to chronic inflammation and poor wound healing. By lowering the levels of RAGE, it can reduce harmful inflammation and help restore normal blood flow, which is crucial for successful diabetic skin healing.

Shows widespread benefits in wound healing in many conditions

Thymosin β4 has demonstrated strong wound-healing properties in a number of conditions, including burns, diabetic wounds, venous leg ulcers, decubitus ulcers and rare skin diseases such as pemphigus (EB), with excellent safety in both animal and human studies. Gao et al. (2022) reviewed a number of studies and found that topical concentrations of around 0.02-0.03% were the most effective and best tolerated [17]. It is naturally present in platelets and wound fluid, where it reduces inflammation, stimulates the formation of new blood vessels, promotes skin cell migration and reduces scar formation. In rodent burn models, subcutaneous injections (30 mg/kg twice a week) significantly accelerated healing, especially when combined with other growth factors such as bFGF. In diabetic wounds in aged mice, topical application of thymosin β4 at 0.01-0.03% improved skin regrowth, blood vessel development and reduced inflammation. Clinical trials showed that 0.02% of topical thymosin β4 accelerated healing of sores from week 4 to week 9 (phase II, 72 participants), and 0.03% led to complete wound closure in 33.3% patients with venous leg ulcers compared to 17.6% in the placebo group. In EB patients, all doses tested (0.01%-0.10%) showed signs of healing, although sample size limitations prevented statistical significance.

In terms of mechanism of action, the substance works in all phases of healing - in the early phase by stabilizing clots and reducing oxidative damage (ROS, NO); in the growth phase by stimulating angiogenesis via VEGF, PI3K/AKT and related pathways; and in the final phase by restoring the skin barrier and preventing excessive collagen or fibroblast accumulation. Unlike other growth factors, this substance can diffuse through tissues and enhances natural healing responses without forcing unnecessary cell growth. Gao et al. also noted the methods of administration and safety: while thymosin β4 administered intravenously has a short half-life (~2.1 hours), advanced systems such as collagen-chitosan sponges and ethosomal gels can prolong its effect. Topical gels of 0.02-0.03% give the best results, but since its action has a bell curve, higher doses may not be better. No safety problems have been demonstrated even with high intravenous doses (up to 1,260 mg) in healthy people, but caution is advised in people with active cancer because of its growth-stimulating properties. For chronic wounds, the authors recommend the use of 0.02-0.03% thymosin β4 topically in slow-release formulations tailored to the frequency of dressing changes [17].

Repairs nerves in diabetic neuropathy

Thymosin β4 restores blood flow and nerve function through activation of the angiopoietin-1/Tie2 signaling pathway. Wang et al (2019) tested thymosin β4 in mice with diabetes and nerve damage (diabetic peripheral neuropathy) [18]. After 4 weeks of treatment, it improved nerve conduction and temperature sensitivity, increased the number of small blood vessels in the sciatic nerve and restored protective nerve barriers. When the researchers blocked the Tie2 receptor, a protein that cooperates with angiopoietin-1 (Ang1) , it stopped working, proving that the Ang1/Tie2 pathway is essential for its nerve repair effect.

Repairs nerves without lowering blood sugar levels

In addition, long-term treatment with thymosin β4 promotes nerve regeneration without affecting blood glucose levels. In a separate 16-week study, Wang et al (2015) showed that although thymosin β4 did not lower blood sugar levels, it improved nerve conduction, sensation and restored healthy nerve structure (axon size and myelin) [19]. In laboratory tests, it helped nerve cells develop longer branches (neurites), and this effect disappeared when Tie2 was blocked, again demonstrating the importance of the Ang1/Tie2 pathway. These studies confirm that it can help repair diabetes-induced nerve damage by improving blood supply and nerve structure, even when blood glucose levels remain unchanged.

Improves bone healing and structural strength in mice

Thymosin β4 promotes bone regeneration, improves ligament repair and mitigates bone loss in inflammation. In a study in mice, Brady et al. (2014) examined how thymosin β4 affects bone healing after leg (fibula) surgery [20]. Mice received either saline or thymosin β4 at a dose of 6 mg/kg injected into the body. On day 21, the bones in the group receiving thymosin β4 were 41% stronger in terms of fracture strength and 25% stiffer than those in the control group, showing stronger and better quality healing. Imaging showed 18% more newly formed mineralized bone and 26% more highly mineralized (mature) bone. Interestingly, the healing tissue (called callus) was 23% smaller, with 47% less old bone and 31% more new spongy bone, suggesting better bone remodeling. Overall, this helped the bone heal faster and it became structurally stronger and more efficient.

Improves ligament healing and mechanical strength

Thymosin β4 promotes ligament repair and increases the tensile strength of the healing tissue. Xu et al (2013) studied rats with surgically cut medial collateral ligament (MCL), the main stabilizing ligament of the knee [21]. They placed a small amount of gel containing just 1 µg of thymosin β4 directly into the injury site. After four weeks, the repaired ligaments in the thymosin β4 group had better collagen structure - they were more organized and had thicker, stronger fibers. These changes made the ligaments mechanically stronger during testing. This improvement is consistent with the known role of thymosin β4 in promoting cell movement, growth of new blood vessels and collagen production, which promote better ligament healing.

Reduces inflammation and bone loss in periodontal disease models

Thymosin β4 reduces inflammation and protects bone by inhibiting excessive bone resorption. Lee et al (2016) examined the effects of thymosin β4 on cells involved in periodontitis and bone loss [22]. In stressed human periodontal ligament cells (PDLC) exposed to hydrogen peroxide, thymosin β4 levels naturally decreased. When additional thymosin β4 was added, it reduced inflammation by lowering the levels of harmful substances such as nitric oxide (NO), prostaglandins (PGE₂) and several pro-inflammatory cytokines (including members of the TNF-α and IL family). It also corrected the RANKL/OPG ratio, which is essential for controlling bone mass loss.

In mouse bone marrow cells stimulated to transform into bone-resorbing cells (osteoclasts), thymosin β4 blocked their formation and turned off genes responsible for bone breakdown. Mechanistically, it inhibited key pathways (MAPK and NF-κB) involved in inflammation and bone loss. In addition, the Wnt5a signaling pathway affected the action of thymosin β4 - blocking Wnt5a enhanced the action of thymosin β4, while the addition of the Wnt5a peptide weakened it. This indicates that it works through complex cell signaling interactions to protect bone and reduce inflammation.

Supports fetal growth and organ development during pregnancy

Thymosin β4 promotes fetal growth and organ development during pregnancy. In a study on pregnant mice, Faa et al (2021) gave them 6 mg/kg thymosin β4 by injection on days 14 and 17 of pregnancy [23]. Young mice born to treated mothers had greater growth and more developed organs - including lungs, heart, kidneys, brain (cerebral cortex) and dorsal striatum - compared to the control group. These results suggest that it helps accelerate organ formation and growth, possibly by improving blood vessel formation (angiogenesis), cell movement and cell differentiation, which may be beneficial in cases of premature birth or delayed development.

Reduces mortality and inflammation in severe sepsis models

Thymosin β4 reduces mortality and systemic inflammation after severe sepsis. Badamchian et al (2003) studied a rodent model of sepsis using a potent immune response inducer (LPS) [24]. After exposure to LPS, the animals had lower levels of thymosin β4, which was also observed in volunteers and patients with septic shock, suggesting that the body consumes thymosin β4 during inflammation. Mice given 100 µg of thymosin β4 at 0, 2 and 4 hours after LPS injection showed lower mortality rates and reduced levels of inflammatory signals such as IL-1β and 6-keto-PGF1α. This suggests that it helps calm the excessive immune response and may protect against lethal inflammation.

Reduces lung scarring and restores lung function in cases of pulmonary fibrosis

In a model of pulmonary fibrosis, thymosin β4 reduces lung scarring and improves respiratory function. In a model of bleomycin-induced lung injury, Yu et al (2025) administered recombinant human thymosin β4 (rhTβ4) to mice for inhalation in the early, middle or late stages of lung injury [25]. In all cases, treatment with thymosin β4 reduced lung scarring, lowered collagen levels and improved lung function. Laboratory studies showed that it slowed the growth and movement of scar-forming cells (fibroblasts), prevented damaging changes in lung lining cells, and controlled TGF-β1, a key molecule in fibrosis. This shows that it works at multiple stages to protect lung structure and function.

Protects the heart and lungs in pulmonary hypertension

In addition, thymosin β4 protects both the heart and lungs in models of pulmonary hypertension. In mice with pulmonary hypertension induced by a toxic compound (monocrotaline), Wei et al (2014) found that it lowered pulmonary blood pressure and reduced enlargement of the right side of the heart (right ventricular hypertrophy) [26]. Molecular tests showed that it affects the Notch3-Col3A1-CTGF signaling pathway, which is involved in blood vessel and tissue remodeling. These findings point to the ability of thymosin β4 to protect the heart and lungs by mitigating harmful changes in blood vessels.

Promotes multi-organ healing with a high safety profile

Thymosin β4 promotes healing and organ protection in multiple systems with a favorable safety profile. Philp and Kleinman (2010) conducted an extensive review showing that thymosin β4 promotes healing and protection of multiple organs without significant side effects [27]. In the case of the eyes, topical application at 5 µg in 5 µl twice a day helped corneal burns heal faster and did not cause unwanted growth of new blood vessels. For the skin, it improved wound healing in diabetic and elderly animals by promoting skin cell movement, collagen production and the growth of new blood vessels. It also helped hair regrowth by activating hair follicles. In the heart, it was tested in both small (mice given 400 ng) and large (pigs given 15 mg) animal models and showed protective effects by reducing tissue damage, increasing heart cell survival and reducing scarring after injury. In models of (LPS-induced) sepsis, it reduced harmful inflammation and increased survival rates. In the brain and central nervous system, it helped protect neurons from damage and promoted the growth of oligodendrocytes, the cells that form myelin - the protective coating around nerve fibers. Mechanistically, thymosin β4 works by blocking inflammatory molecules, stopping tissue-degrading enzymes (MMPs), balancing key survival signals , such as NF-κB and Akt, and stimulating stem cell activity for tissue repair. Importantly, safety studies in rats and monkeys showed no adverse effects even at high doses (250 mg/kg), indicating a large safety margin and great potential for use in humans [27].

Prevents lung damage during aortic reperfusion

Thymosin β4 prevents reperfusion-induced lung injury after aortic obstruction. In a model of aortic ischemic injury, Yaman et al (2019) administered 10 mg/kg thymosin β4 to rats one hour before aortic blockage or 15 minutes before blood flow was restored [28]. Both timing strategies worked equally well. It lowered oxidative stress, reduced inflammatory cytokines, improved antioxidant levels in the lungs and blood, and reduced tissue damage. These results suggest that it is effective in preventing acute lung damage caused by interruptions in blood flow, especially during surgery or trauma.

Reduces esophageal scarring after surgery

Topically applied thymosin β4 gel alleviates swallowing difficulties after esophageal surgery. In a study by Wang et al (2019), eight pigs underwent surgery to remove the inner lining of the esophagus (perianal ESD), which usually causes strictures [29]. Four pigs were treated with a topical gel containing thymosin β4, and four were untreated. All developed strictures, but in those that received thymosin β4, the strictures were less severe, required fewer balloon procedures to reopen the esophagus (p = 0.002) and healed faster (p = 0.012). The researchers believe it worked by reducing scar tissue and promoting cell movement and healing, reducing the buildup of thick collagen that causes constriction. No side effects were reported.

Preserves blood vessel structure and prevents aortic aneurysms

Thymosin β4 protects the integrity of blood vessels and helps prevent the development of aortic aneurysms. Munshaw et al (2021) studied mice lacking thymosin β4 and found that they had weaker blood vessel walls and were more likely to develop aortic aneurysms, especially after exposure to angiotensin II [30]. Without thymosin β4, the vessel wall cells (VSMCs) changed to a more deleterious type causing scarring. This was due to excessive recycling of a receptor called PDGFRβ, which is normally controlled by thymosin β4. When the researchers used imatinib, a drug that blocks PDGFRβ, it reduced the damage in mice lacking thymosin β4. This showed that thymosin β4 normally helps control vascular remodeling by maintaining a balance of growth signals.

Restores the intestinal barrier and reduces inflammation in CGD models

In chronic granulomatous disease, thymosin β4 restores autophagy and strengthens the intestinal barrier to alleviate intestinal inflammation. In models of chronic granulomatous disease (CGD), a genetic immune disorder, Renga et al. (2019) treated human and mouse immune cells with thymosin β4 and CGD mice [31]. The treatment restored a protective protein (HIF-1α) and induced a special type of cell clearing process (non-canonical autophagy) through DAPK1. This improved the protective intestinal lining, reduced inflammation, prevented the formation of harmful tissue nodules (granulomas) and improved survival. The results suggest that this helps balance inflammation and cell clearance in the gut, which is crucial in CGD.

Slows atherosclerosis and maintains vascular stability

Thymosin β4 slows the progression of atherosclerosis and preserves blood vessel health. In mice susceptible to arteriosclerosis (ApoE- /- ), Munshaw et al (2023) compared normal mice with mice lacking thymosin β4 [32]. Mice lacking thymosin β4 developed larger atherosclerotic plaques in the arteries, more damage in the middle layer of the vessels, and their smooth muscle cells lost their healthy state. It was normally found in cells that keep blood vessels healthy and functional, but its levels dropped in diseased cells. Without thymosin β4, the deleterious growth signal (PDGFRβ) became overactive due to poor receptor control, causing unhealthy vascular remodeling. This suggests that it plays a protective role in maintaining arterial stability and slowing disease progression.

Stabilizes blood vessels and improves survival in cases of sepsis

In sepsis, thymosin β4 protects blood vessel support cells, improving vascular stability and survival outcomes. Bongiovanni et al (2015) used a gene therapy approach to increase thymosin β4 levels in mice two weeks before they were given a sepsis-inducing agent (LPS) [33]. Treated mice had lower disease score, better blood pressure and fewer leaking vessels. Most importantly, they lived longer and retained pericytes, the support cells that surround small blood vessels in the heart and muscles. This showed that it protects the blood vessel barrier, keeps the support cells in place and prevents dangerous fluid leakage during sepsis.

Prevents lung fibrosis and cell damage in inflammatory models

In addition, thymosin β4 reduces lung damage and fibrosis in models of severe inflammation. In a model of LPS-induced lung damage, Tian et al (2022) used gene therapy to deliver thymosin β4 to mice [34]. The treated mice showed less oxidative damage, less collagen accumulation and less inflammation. In cultured human lung cells in the laboratory, it helped repair damaged mitochondria, reduced activation of cell danger sensors (inflammasomes) and slowed cellular transformations leading to fibrosis. It also prevented fibroblast proliferation and scar formation. Overall, it maintained healthy lung cell activity and blocked several pathways leading to long-term lung damage.

Accelerates wound healing by activating enzymes responsible for tissue remodeling

Thymosin β4 accelerates wound healing by activating enzymes involved in tissue remodeling and debridement. In a study on wound healing, Philp et al (2006) applied thymosin β4 to skin injuries in mice, and also tested it on human skin and immune cells in the laboratory [35]. It increased the production of enzymes called MMP-1, MMP-2 and MMP-9, which break down damaged tissue and help new cells grow. These effects were observed in various cell types, such as keratinocytes, fibroblasts, endothelial cells and activated monocytes. A small portion of the thymosin β4 protein (amino acids 17-23) was enough to trigger this reaction. This means that it helps wound healing not only by promoting cell movement and growth, but also by clearing the site of injury to make room for new tissue. The findings show how thymosin β4 links the control of internal cell structure to the cleansing and rebuilding of the skin during healing.

Dosage guidelines for thymosin beta 4

Early clinical studies have shown that thymosin β4 can be safely used in a wide range of doses, with the appropriate amount depending on the route of administration and the type of tissue being treated. For intravenous use, the first human studies using the recombinant version (NL005) tested doses ranging from 0.05 µg/kg to 25 µg/kg in a single dose and daily infusions at doses of 0.5-5 µg/kg for ten days. Blood levels increased proportionally, and the drug had a short half-life of about two hours, indicating a predictable effect without accumulation in the body. In an earlier study using chemically synthesized thymosin β4, much higher intravenous doses ranging from 42 mg to 1260 mg daily for two weeks were administered without serious side effects, indicating a wide safety margin for systemic use.

For eye diseases, 0.1% thymosin β4 eye drop solution (about 1 mg/mL) applied 4-6 times a day relieved symptoms of severe or induced dry eye without entering the bloodstream in significant amounts. For chronic skin wounds, three phase 2 studies showed that a gel of 0.02-0.03% applied once daily was most effective in accelerating healing, while both lower (0.01%) and higher (0.1%) doses were less effective. In addition, in a study on pigs, injection of 0.1% gel into the esophageal region helped prevent scarring after surgical resection, suggesting the possibility of more localized treatments.

Overall, excellent safety has been demonstrated. In a study of the recombinant product, just over half of the participants experienced mild and transient changes in laboratory or ECG results - similar to placebo - with no serious or dose-related side effects. Any immunologic reactions were mild and resolved over time. In the high-dose study of synthetic thymosin β4, the only complaints were mild dizziness or discomfort at the injection site, with no signs of organ damage. Eye drops and skin gels were also well tolerated; no drug-related eye irritation was observed, and the gel caused minor itching or redness of the skin to the same extent as placebo. Importantly, repeated use did not lead to accumulation of the substance in the body, immune reactions or any laboratory signs of organ damage.

Since human studies are still in the early stages, most safety warnings are based on the precautionary principle. It should not be used in people who are allergic to the peptide or its components. Although no risk of cancer has been found so far, even in high-risk patients such as those with pemphigus, its ability to promote cell movement and blood vessel formation means it should be used with caution, especially in people with active cancer, and preferably only under controlled study conditions. The safety of thymosin β4 use during pregnancy or lactation has not been studied, so it is best avoided unless the benefits clearly outweigh the risks. Finally, since there are no pharmacokinetic data for patients with severe liver or kidney disease, physicians should start treatment with the lowest micro intravenous dose and closely monitor patients if treatment is necessary.

Applications

Early clinical and laboratory studies show that thymosin β4 is generally safe and promotes healing in a number of ways. When administered intravenously - in the form of lab-made thymosin β4 or a similar version called NL005 - it was well tolerated by healthy subjects, even with repeated administration. The drug moved through the body in a predictable manner, had a short life span in the blood without accumulating, and elicited only mild and short-lived immune reactions. When used in the form of eye drops, it showed promising results in treating ocular surface diseases. In phase 2 studies and special use cases, it improved symptoms, reduced ocular surface damage (measured by staining) and helped improve tear quality. However, in one study using the CAE™ model (a dry eye syndrome testing system), it failed to achieve two primary goals, but still succeeded in several important secondary measurements.

In skin treatment, creams or gels with thymosin β4 in moderate doses (about 0.02-0.03%) helped sores and venous ulcers heal faster in phase 2 studies. These results are consistent with previous laboratory studies showing that it helps skin cells (keratinocytes) move into the wound area, stimulates the growth of new blood vessels, better organizes collagen fibers and reduces scar formation.

In conclusion, thymosin β4 promises to be a unique therapeutic agent that not only helps repair damaged tissues, but also reduces harmful inflammation. Researchers must continue to observe the long-term safety of this agent, especially in people who may be at risk for cancer. They should also look for biological signs (biomarkers) that would help identify patients who may benefit most, and determine appropriate doses. If these efforts confirm the benefits so far, it could become a valuable new option for treating eye and wound diseases. And because it is safe when administered intravenously, it could also be useful in emergency situations where the body needs rapid protection and healing signals, such as in the case of heart attacks or strokes.

Disclaimer

This article was written for educational purposes and is intended to raise awareness of the substance under discussion. It is important to note that the article is about the substance in general - it is not a description of a specific product (chemical reagent). We do not suggest the use of chemical reagents on humans - this is prohibited by law, for a product to be used for treatment it must be registered as a drug. The information contained in the text is based on available scientific research and is not intended to serve as medical advice or promote self-medication. The reader should consult any health and treatment decisions with a qualified health professional.

References

1. https://pubchem.ncbi.nlm.nih.gov/compound/Thymosin-beta4#section=NCI-Thesaurus-Tree
2. Wang, X., Liu, L., Qi, L., Lei, C., Li, P., Wang, Y., Liu, C., Bai, H., Han, C., Sun, Y. and Liu, J. (2021). First phase I human, randomized, double-blind, single- and multiple-dose study of recombinant human thymosin β4 in healthy Chinese volunteers. Clinical and Translational Science, 14(5), 1949-1962. https://doi.org/10.1111/cts.13050 
3. Sosne, G., Dunn, S. P., and Kim, C. (2015). Thymosin β4 significantly relieves symptoms of severe dry eye syndrome in a randomized phase II study. Cornea, 34(5), 491-496. https://doi.org/10.1097/ICO.0000000000000379
4. Ruff, D., Crockford, D., Girardi, G., and Zhang, Y. (2010). Randomized, placebo-controlled study of single and multiple doses of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences, 1194, 223-229. https://doi.org/10.1111/j.1749-6632.2010.05474.x
5. Guarnera, G., DeRosa, A. and Camerini, R. (2010). Effect of thymosin treatment on venous ulcers. Annals of the New York Academy of Sciences, 1194, 207-212. https://doi.org/10.1111/j.1749-6632.2010.05490.x
6. Sosne, G. and Ousler, G. W. (2015). Thymosin beta 4 ophthalmic solution for the treatment of dry eye syndrome: a randomized, placebo-controlled phase II clinical trial conducted using a controlled adverse environment (CAE™) model. Clinical Ophthalmology, 9, 877-884. https://doi.org/10.2147/OPTH.S80954 https://www.tandfonline.com/doi/full/10.2147/OPTH.S80954
7. Dunn, S. P., Heidemann, D. G., Chow, C. Y. C., Crockford, D., Turjman, N., Angel, J., Allan, C. B., and Sosne, G. (2010). Treatment of chronic non-healing neurotrophic corneal epithelial defects with thymosin beta 4. Archives of Ophthalmology, 128(5), 636-638. https://doi.org/10.1001/archophthalmol.2010.71https://pismin.com/10.1001/archophthalmol.2010.53 
8. Kleinman, H. K. and Sosne, G. (2016). Thymosin β4 promotes skin healing. In Vitamins and hormones (vol. 102, pp. 251-275). Elsevier. https://doi.org/10.1016/bs.vh.2016.04.005 https://pismin.com/10.1016/bs.vh.2016.04.005
9. Treadwell, T., Kleinman, H. K., Crockford, D., Hardy, M. A., Guarnera, G. T. and Goldstein, A. L. (2012). The regenerative peptide thymosin β4 accelerates skin healing rates in preclinical animal models and patients. Annals of the New York Academy of Sciences, 1270, 37-44. https://doi.org/10.1111/j.1749-6632.2012.06717.x https://pubmed.ncbi.nlm.nih.gov/23050815/
10. Guarnera, G., De Rosa, A. and Camerini, R. (2007). Thymosin β 4 and venous ulcers: clinical comments on a European prospective, randomized study of safety, tolerability, and improved healing. Annals of the New York Academy of Sciences, 1112, [pages in preparation]. https://doi.org/10.1196/annals.1415.003   https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1415.003
11. Yang, W. S., Kang, S., Sung, J., and Kleinman, H. K. (2019). Thymosin β4: potential in the treatment of pemphigus and other severe skin injuries. European Journal of Dermatology, 29(5), 459-467. https://doi.org/10.1684/ejd.2019.3642https://stm.cairn.info/revue-european-journal-of-dermatology-2019-5-page-459?lang=en 
12. Zhu, J., Su, L.-P., Ye, L., Lee, K.-O. and Ma, J.-H. (2012). Thymosin beta 4 alleviates hyperglycemia and improves insulin resistance in KK Cg-Ay/J mice. Diabetes Research and Clinical Practice, 96(1), 53-59. https://doi.org/10.1016/j.diabres.2011.12.009https://pubmed.ncbi.nlm.nih.gov/22217673/ 
13. Wang, L., Chopp, M., Szalad, A., Liu, Z., Lu, M., Zhang, L., Zhang, J., Zhang, R. L., Morris, D., and Zhang, Z. G. (2012). Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice. Neurobiology of Disease, 48(3), 546-555. https://doi.org/10.1016/j.nbd.2012.08.002 https://pubmed.ncbi.nlm.nih.gov/22922221/
14. Su, L., Kong, X., Loo, S., Gao, Y., Liu, B., Su, X., Dalan, R., Ma, J. and Ye, L. (2022). Thymosin beta-4 improves endothelial function and repair capacity of diabetic endothelial cells cultured from induced pluripotent stem cells of patients. Stem Cell Research & Therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-xhttps://pubmed.ncbi.nlm.nih.gov/35012642/ 
15. Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A. L., and Kleinman, H. K. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote skin wound healing in diabetic db/db and aged mice. Wound Repair and Regeneration, 11(1), 19-24.https://doi.org/10.1046/j.1524-475x.2003.11105.xhttps://pubmed.ncbi.nlm.nih.gov/12581423/ 
16. Kim, S. and Kwon, J. (2014). Thymosin beta 4 improves skin burn healing by downregulating advanced glycation product receptors in db/db mice. Biochimica et Biophysica Acta (BBA) - General Topics, 1840.(12), 3452-3459. https://doi.org/10.1016/j.bbagen.2014.09.013https://pubmed.ncbi.nlm.nih.gov/25230158/ 
17. Gao, Y. X., Wang, L. F., Ba, S. J., Cao, J. L., Li, F., Li, B., and Zhou, B. (2022). Zhonghua shao shang yu chuang mian xiu fu za zhi, 38(4), 378–384. https://doi.org/10.3760/cma.j.cn501120-20210221-00059 https://pmc.ncbi.nlm.nih.gov/articles/PMC11704510/
18. Wang, L., Chopp, M., Szalad, A., Lu, X., Lu, M., Zhang, T., & Zhang, Z. G. (2019). The angiopoietin-1/Tie2 signaling pathway contributes to the therapeutic effect of thymosin β4 on diabetic peripheral neuropathy. Neurological examinations, 147, 1-8. https://doi.org/10.1016/j.neures.2018.10.005 https://pubmed.ncbi.nlm.nih.gov/30326249/
19. Wang, L., Chopp, M., Jia, L., Lu, X., Szalad, A., Zhang, Y., Zhang, R., & Zhang, Z. G. (2015). Therapeutic benefits of prolonged thymosin β4 treatment are independent of blood glucose levels in mice with diabetic peripheral neuropathy. Journal of Diabetes Research, 2015, 173656. https://doi.org/10.1155/2015/173656https://pubmed.ncbi.nlm.nih.gov/25945352/ 
20. Brady, R. D., Grills, B. L., Schuijers, J. A., Ward, A. R., Tonkin, B. A., Walsh, N. C., and McDonald, S. J. (2014). Thymosin β4 administration accelerates fracture healing in mice. Journal of Orthopaedic Research, 32(10), 1277-1282. https://doi.org/10.1002/jor.22686https://pubmed.ncbi.nlm.nih.gov/25042765/ 
21. Xu, B., Yang, M., Li, Z., Zhang, Y., Jiang, Z., Guan, S., and Jiang, D. (2013). Thymosin β4 accelerates healing of medial collateral ligament injuries in rats. Regulatory Peptides, 184, 1-5. https://doi.org/10.1016/j.regpep.2013.03.026 https://pubmed.ncbi.nlm.nih.gov/23523891/
22. Lee, S. I., Yi, J. K., Bae, W. J., Lee, S., Cha, H. J., and Kim, E. C. (2016). Thymosin beta-4 inhibits osteoclast differentiation and inflammatory responses in human periodontal ligament cells. PLoS ONE, 11(1), e0146708. https://doi.org/10.1371/journal.pone.0146708 https://pubmed.ncbi.nlm.nih.gov/26789270/
23. Faa, G., Piras, M., Mancuso, L., Coni, P., Pichiri, G., Orrù, G., Fanni, D., Gerosa, C., Cao, G., Taibi, R., Pavone, P. and Castagnola, M. (2021). Prenatal administration of thymosin beta-4 improves fetal development and prevents side effects of preterm birth. European Review for Medical and Pharmacological Sciences, 25(1), 431–437. https://doi.org/10.26355/eurrev_202101_24411 https://pubmed.ncbi.nlm.nih.gov/33506933/
24. Badamchian, M., Fagarasan, M. O., Danner, R. L., Suffredini, A. F., Damavandy, H., and Goldstein, A. L. (2003). Thymosin beta(4) reduces mortality and inhibits inflammatory mediators in endotoxin-induced septic shock. International Immunopharmacology, 3(8), 1225-1233. https://doi.org/10.1016/S1567-5769(03)00024-9https://pubmed.ncbi.nlm.nih.gov/12860178/ 
25. Yu, R., Li, S., Chen, L., Hu, E., Chai, D., Liu, Z., Zhang, Q., Mao, Y., Zhai, Y., Li, K., Liu, Y., Li, X., Zhou, H., Yang, C. and Xu, J. (2025). Inhaled exogenous thymosin beta 4 inhibits bleomycin-induced pulmonary fibrosis in mice via TGF-β1 signaling pathway. Journal of Pharmacy and Pharmacology, 77(4), 582-592. https://doi.org/10.1093/jpp/rgae143https://pubmed.ncbi.nlm.nih.gov/39579076/ 
26. Wei, C., Kim, I. K., Li, L., Wu, L., & Gupta, S. (2014). Thymosin beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. PLoS ONE, 9(11), e110598. https://doi.org/10.1371/journal.pone.0110598https://pubmed.ncbi.nlm.nih.gov/25412097/ 
27. Philp, D. and Kleinman, H. K. (2010). Animal studies with thymosin β4, a multifunctional peptide for tissue repair and regeneration. Annals of the New York Academy of Sciences, 1194(1), 81–86. https://doi.org/10.1111/j.1749-6632.2010.05479.x https://pismin.com/10.1111/j.1749-6632.2010.05479.x
28. Yaman, O. M., Guner, I., Guntas, G., Sonmez, O. F., Tanriverdi, G., Cakiris, A., Aksu, U., Akyol, S., Guzel, E., Uzun, H., Yelmen, N., & Sahin, G. (2019). Protective effects of thymosin β4 against acute lung injury induced by abdominal aortic ischemia and reperfusion in rats. Medicina (Kaunas), 55(5), 187. https://doi.org/10.3390/medicina55050187 https://pubmed.ncbi.nlm.nih.gov/31121838/
29. Wang, H., Shuai, Q., Tang, J., Long, D., Xu, C., Liu, F. and Li, Z.-S. (2019). Topical injection of thymosin β4 gel prevents esophageal stricture after endoscopic submucosal resection in a porcine model. Digestive Diseases, 37(2), 87-92. https://doi.org/10.1159/000492216 https://pubmed.ncbi.nlm.nih.gov/30428463/
30. Munshaw, S., Bruche, S., Redpath, A. N., Jones, A., Patel, J., Dubé, K. N., Lee, R., Hester, S. S., Davies, R., Neal, G., Handa, A., Sattler, M., Fischer, R., Channon, K. M., and Smart, N. (2021). Thymosin β4 protects against aortic aneurysm through endocytic regulation of growth factor signaling. Journal of Clinical Investigation, 131(10), e127884. https://doi.org/10.1172/JCI127884 https://pubmed.ncbi.nlm.nih.gov/33784254/
31. Renga, G., Oikonomou, V., Moretti, S., Stincardini, C., Bellet, M. M., Pariano, M., Bartoli, A., Brancorsini, S., Mosci, P., Finocchi, A., Rossi, P., Costantini, C., Garaci, E., Goldstein, A. L., and Romani, L. (2019). Thymosin β4 promotes autophagy and repair by stabilizing HIF-1α in chronic granulomatous disease. Life Science Alliance, 2(6), e201900432. https://doi.org/10.26508/lsa.201900432 https://pubmed.ncbi.nlm.nih.gov/31719116/
32. Munshaw, S., Redpath, A. N., Pike, B. T. and Smart, N. (2023). Thymosin β4 preserves the vascular smooth muscle phenotype in atherosclerosis by regulating low-density lipoprotein-related protein 1 (LRP1). International Immunopharmacology, 115, 109702. https://doi.org/10.1016/j.intimp.2023.109702 https://pubmed.ncbi.nlm.nih.gov/37724952/
33. Bongiovanni, D., Ziegler, T., D’Almeida, S., Zhang, T., Ng, J. K. M., Dietzel, S., Hinkel, R. and Kupatt, C. (2015). Thymosin β4 ameliorates microcirculatory and hemodynamic destabilization in sepsis. Expert Opinion on Biological Therapy, 15(Suppl 1), S203-S210. https://doi.org/10.1517/14712598.2015.1006193https://pubmed.ncbi.nlm.nih.gov/25604254/ 
34. Tian, Z., Yao, N., Wang, F., and Ruan, L. (2022). Thymosin β4 inhibits LPS-induced pulmonary fibrosis in mice by attenuating oxidative damage and reducing inflammation. Inflammation, 45(1), 59–73. https://doi.org/10.1007/s10753-021-01528-6 https://pubmed.ncbi.nlm.nih.gov/34414534/
35. Philp, D., Scheremeta, B., Sibliss, K., Zhou, M., Fine, E. L., Nguyen, M., Wahl, L., Hoffman, M. P., and Kleinman, H. K. (2006). Thymosin beta4 promotes expression of matrix metalloproteinases during wound healing. Journal of Cellular Physiology, 208(1), 195-200. https://doi.org/10.1002/jcp.20650https://pubmed.ncbi.nlm.nih.gov/16607611/ 

Chemical materials for analytical testing are available from a separate section of the website.